Pomerantz LLP Investigates Securities Claims Against Nurix Therapeutics, Inc.
Pomerantz LLP has announced an investigation into Nurix Therapeutics, Inc. regarding potential securities fraud or other unlawful business practices.
Stocks · News reference
Nurix Therapeutics announced it will present updated clinical data from its Phase 1a/1b trial of bexobrutideg (NX-5948) for the treatment of relapsed/refractory CLL/SLL.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pomerantz LLP has announced an investigation into Nurix Therapeutics, Inc. regarding potential securities fraud or other unlawful business practices.
Nurix Therapeutics has appointed Dr. Arati V. Rao as its new Chief Medical Officer to lead the company's clinical development organization.
Nurix Therapeutics announced that company management will participate in fireside chats at three upcoming investor conferences in November and December 2026.
Ark Invest included Nurix Therapeutics (NRIX) among its recent stock purchases in its actively managed ETFs.
An insider at Nurix Therapeutics has sold shares of the company's stock, according to a recent SEC filing.
Sanofi has notified Nurix Therapeutics of its decision to terminate the Phase 1 clinical trial and development program for the oral STAT6 degrader SAR448272.